Does intracellular Ca++ overload underlie diastolic dysfunction in hypertrophic cardiomyopathy?
Myocardial tissue obtained at the time of surgery or transplantation from patients with hypertrophic cardiomyopathy
In vitro assessment of isometric contractions, electrophysiologic properties, and intracellular calcium transients, including exposure to pacing, digitalis, verapamil, and forskolin
Control myocardium obtained from patients without heart disease
Action potentials, Ca++ transients, and isometric contraction and relaxationsurrogate
Intracellular calcium overload contributes to diastolic dysfunction in hypertrophic cardiomyopathy, providing a mechanistic rationale for the poor tolerance of tachycardia and the therapeutic benefit of calcium-lowering agents like verapamil.
We tested the hypothesis that intracellular Ca++ ( Ca++i) overload underlies the diastolic dysfunction of patients with hypertrophic cardiomyopathy. Myocardial tissue was obtained at the time of surgery or transplantation from patients with hypertrophic cardiomyopathy and was compared with control myocardium obtained from patients without heart disease. The isometric contractions and electrophysiologic properties of all myocardial specimens were recorded by standard techniques and Ca++i was measured with the bioluminescent calcium indicator aequorin. In contrast to the controls, action potentials, Ca++ transients, and isometric contraction and relaxation were markedly prolonged in the hypertrophic myocardium, and the Ca++ transients consisted of two distinct components. At 38 degrees C and 1 Hz pacing frequency, a state of relative Ca++ overload appeared develop, which produced a rise in end-diastolic Ca++i, incomplete relaxation, and fusion of twitches with a resultant decrease in active tension development. We also found that drugs with increase Ca++i, such as digitalis, exacerbated these abnormalities, whereas drugs that lower Ca++i, such as verapamil, or agents that increase cyclic AMP, such as forskolin, prevented them. These results may explain why patients with hypertrophic cardiomyopathy tolerate tachycardia poorly, and may have important implications with regard to the pharmacologic treatment of patients with hypertrophic cardiomyopathy.
Building similarity graph...
Analyzing shared references across papers
Loading...
Judith K. Gwathmey
Heart Failure & Transplant
Sanford E. Warren
Brigham and Women's Hospital
George M. Briggs
University of Arkansas at Little Rock
Journal of Clinical Investigation
Brigham and Women's Hospital
Mayo Clinic in Arizona
Dana (United States)
Building similarity graph...
Analyzing shared references across papers
Loading...
Gwathmey et al. (Fri,) studied this question.
synapsesocial.com/papers/69d94f08c7f0c3ae80a3ccb4 — DOI: https://doi.org/10.1172/jci115061